An unusual glitch occurred this week on Google Inc (NASDAQ GOOG)’s image search engine that had tongues wagging from Twitter to Reddit. When users would search for an image, the same result of a Russian accident would display. This morning when someone searched for an image – any image – what popped up on screen was a the same image of a Russian car crash. … Continue reading Stock Analysis: A Glitch by Google (NASDAQ GOOG)
A new study suggests that many consumers remain cautious about the prospect of purchasing or using digital currency. The report was written by the Massachusetts Division of Banks (MDB) in conjunction with the Conference of State Bank Supervisors (CSBS), who canvassed more than 1,000 consumers with an online survey that focused on digital currency.
The CSBS, which is a national organization of bank regulators, previously held a hearing on the topic of digital currency in May. The survey data shows that while a slim majority of respondents (51%) have heard of digital currency, 65% stated that they are “unlikely” to ever buy or use a technology like bitcoin.
Eighteen percent of participants indicated that they were “likely” or “very likely” to use a digital currency, and only 3% of those who had heard of bitcoin said they had actually bought some. According to the CSBS, the Emerging Payments Task Force – the organization’s working group that focuses, in part, on bitcoin – will use the data as it continues to develop its policies for digital currency.
In a statement, the chairman of the task force and Massachusetts Commissioner of Banks David Cotney said that the study fits into the broader research phase currently taking place. He explained: “State regulators welcome innovations that lead to greater choice and lower costs, but we also want to understand any consumer and marketplace risks as we evaluate the overall benefits of virtual currencies.”
Fears regarding security and regulation, as well as concerns regarding the lack of consumer protections afforded in the traditional financial system, were highlighted in the study. Sixty-one percent said that the overall security of their bitcoins would factor significantly into whether or not they used or purchased some, while 43% of study participants stated that bitcoin’s tax status would be a major factor. Forty-eight percent reported that concerns of insurance might stop them from buying bitcoin.
Watch this video for more “News on Bitcoin”.
Continue reading “Bitcoin Review: 65% of US Won’t Buy Bitcoins”
Indigo analyst N. Landell-Mills is impressed with the latest results from Facebook Inc (NASDAQ FB) and Google Inc (NASDAQ GOOG), as each have managed to keep revenue growth high in competitive market segments, but that doesn’t mean he thinks that either company is an attractive investment. He expects the combination of slowing growth and the end of QE to cause double digit percentage point drops … Continue reading Stock Making Headlines: Facebook FB Stock is Great But Overvalued
Apple Inc (NASDAQ AAPL) is expected to unveil the much-anticipated iPhone 6 at an event on Sept. 9, and analysts have been expecting great things for the company’s stock. They say that this time, shares won’t fall after the announcement. Instead, many believe the exact opposite thing will happen. Analysts believe that with the iPhone 6 launch, Apple stock may not see the decline it … Continue reading Stock in Focus: A Look at Apple (NASDAQ AAPL) Stock before iPhone 6 Launch
Kite Pharma, Inc (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin’s lymphoma in the Aug 25, 2014 issue of the American Society of Clinical Oncology’s Journal of Clinical Oncology. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate. According to Kite Pharma, out of 13 patients with advanced B-cell … Continue reading Active Biotech Stocks: Kite Pharma Drug
Shares of Amicus Therapeutics (FOLD) soared 20.4% after the company announced positive data from its second phase III study (Study 012) on the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations. The phase III study is evaluating the use of oral migalastat to standard-of-care enzyme replacement therapies (ERTs) − Sanofi’s (SNY) Fabrazyme and Shire’s (SHPG) Replagal − for Fabry disease. Eighteen-month … Continue reading Biotech Stocks: Amicus Therapeutics (FOLD) Soars High After Positive Results
